Biomnis >> Latest News >> New Test: Prostate Health Index (PHI)

New Test: Prostate Health Index (PHI)

Sidebar Image

Biomnis Ireland is pleased to announce the availability of the Prostate Health Index (PHI).

PHI is a mathematical formula that combines total PSA, free PSA and a new serum marker known as [-2] proPSA into a single score that can be used to aid in clinical decision-making, and is estimated to be 3 times more specific in detecting prostate cancer in patients than PSA screening alone.

A new serum marker, [-2]proPSA is strongly expressed in the peripheral zone of cancerous tissues of the prostate and is rarely expressed in the transition zone, which is the main site of most benign prostatic hyperplasia. Recent studies have concluded that the phi outperformed prostate-specific antigen (PSA) and free/total prostate specific antigen (%fPSA) tests individually in:

  • Predicting the presence of clinically significant prostate cancer and improving prostate cancer detection thus reducing unnecessary biopsy and over-detection of indolent prostate cancer.
  • Improving the prediction of high-grade and clinically-significant prostate cancer thus highlighting a significant correlation between phi and the Gleason score.


If you would like further information about this test please click here to download our PHI brochure or contact our Sales Department on (01) 295 8545 or email us at sales@biomnis.ie.  , and is estimated to be 3 times more specific in detecting prostate cancer in patients than PSA screening alone.

A new serum marker, [-2]proPSA is strongly expressed in the peripheral zone of cancerous tissues of the prostate and is rarely expressed in the transition zone, which is the main site of most benign prostatic hyperplasia. Recent studies have concluded that the phi outperformed prostate-specific antigen (PSA) and free/total prostate specific antigen (%fPSA) tests individually in:

  • Predicting the presence of clinically significant prostate cancer and improving prostate cancer detection thus reducing unnecessary biopsy and over-detection of indolent prostate cancer.
  • Improving the prediction of high-grade and clinically-significant prostate cancer thus highlighting a significant correlation between phi and the Gleason score.


If you would like further information about this test contact our Sales Department on (01) 295 8545 or email us at sales@eurofins-biomnis.ie.